Back to Search Start Over

Efficacy and safety analysis in metastatic cancer patients treated with multiple courses of repeat radiation therapy

Authors :
Maiwand Ahmadsei
Sebastian M. Christ
Tiuri E. Kroese
Anja Kühnis
Jonas Willmann
Panagiotis Balermpas
Nicolaus Andratschke
Stephanie Tanadini-Lang
Matthias Guckenberger
Source :
Clinical and Translational Radiation Oncology, Vol 43, Iss , Pp 100687- (2023)
Publication Year :
2023
Publisher :
Elsevier, 2023.

Abstract

Background and purpose: Due to advances in oncology, a growing proportion of patients is treated with repetitive courses of radiotherapy. The aim of this study is to analyze whether radiotherapy maintains its safety and efficacy profile in patients treated with multiple repeat courses of irradiation. Material and methods: All patients treated between 2011 and 2019 at our institution were screened for a minimum of five repeat irradiation courses, to analyze treatment characteristics, survival, safety and efficacy. The type of re-irradiation was classified according to ESTRO-EORTC consensus guidelines. Results: A total of n = 112 patients receiving n = 660 radiotherapy courses were included in this retrospective cohort study. The most frequent primary tumors were lung cancer in 41.9 % (n = 47) and malignant melanoma in 8.9 % (n = 10). The most frequent re-irradiation types were repeat irradiation and Type 2 re-irradiation in 309 (46.8 %) and 113 (17.1 %) cases, respectively. Median survival after the first course of radiotherapy was 3.6 (0.3–13.4) years. Response to radiotherapy was observed in 548 (83.0 %) cases and CTCAE toxicity grade ≥ 3 was observed in 21 (3.2 %) cases. An increasing number of RT courses (HR: 1.30, p=

Details

Language :
English
ISSN :
24056308
Volume :
43
Issue :
100687-
Database :
Directory of Open Access Journals
Journal :
Clinical and Translational Radiation Oncology
Publication Type :
Academic Journal
Accession number :
edsdoj.6ea6b9238c7b417ab9b788c4f2ca7a4c
Document Type :
article
Full Text :
https://doi.org/10.1016/j.ctro.2023.100687